A phase I/II study of SDZ PSC 833 (PSC) in combination with daunorubicin (D) and cytarabine in refractory acute myelogenous leukemia (AML).

被引：0
|
作者：
Liliemark, J
Bjorkholm, M
Uden, AM
Hast, R
Paul, C
Simonsson, B
Tidefelt, U
Juliusson, G
Hedenus, M
Evensen, S
Tangen, JM
Sjo, M
Nesthus, I
Hestdal, K
机构：
[1] KAROLINSKA HOSP,DEPT ONCOL,S-10401 STOCKHOLM,SWEDEN
[2] KAROLINSKA HOSP,DEPT HEMATOL,S-10401 STOCKHOLM,SWEDEN
[3] SODER SJUKHUSET,DEPT HEMATOL,STOCKHOLM,SWEDEN
[4] DANDERYD HOSP,DEPT HEMATOL,STOCKHOLM,SWEDEN
[5] HUDDINGE HOSP,DEPT HEMATOL,STOCKHOLM,SWEDEN
[6] UNIV UPPSALA HOSP,DEPT HEMATOL,UPPSALA,SWEDEN
[7] REG HOSP,DEPT HEMATOL,OREBRO,SWEDEN
[8] LINKOPING UNIV HOSP,DEPT HEMATOL,S-58185 LINKOPING,SWEDEN
[9] SUNDSVALL HOSP,DEPT HEMATOL,SUNDSVALL,SWEDEN
[10] ULLEVAL HOSP,RIKSHOSP,DEPT HEMATOL,OSLO,NORWAY
[11] REG HOSP,DEPT HEMATOL,TROMSO,NORWAY
[12] HAUKELAND HOSP,DEPT HEMATOL,N-5021 BERGEN,NORWAY
[13] SANDOZ,DEPT HEMATOL,OSLO,NORWAY
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：854 / 854
页数：1
相关论文
共 50 条
  • [31] Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia
    Xu, WL
    Shen, HL
    Ao, ZF
    Chen, BA
    Xia, W
    Gao, F
    Zhang, YN
    LEUKEMIA RESEARCH, 2006, 30 (04) : 407 - 413
  • [32] Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies (vol 18, pg 1124, 2000)
    Fracasso
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) : 2793 - 2793
  • [33] Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).
    DiPersio, John F.
    Erba, Harry Paul
    Larson, Richard A.
    Luger, Selina M.
    Mangan, Kenneth Francis
    Tallman, Martin S.
    Brill, Jeffrey Mark
    Vuagniaux, Gregoire
    Rouits, Elisabeth
    Zanna, Claudio
    Sorensen, J. Mei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)
    Advani, Anjali S.
    Li, Hongli
    Michaelis, Laura C.
    Medeiros, Bruno C.
    Liedtke, Michaela
    List, Alan F.
    O'Dwyer, Kristen
    Othus, Megan
    Erba, Harry P.
    Appelbaum, Frederick R.
    LEUKEMIA RESEARCH, 2018, 67 : 17 - 20
  • [35] A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations
    Takahashi, Koichi
    Jabbour, Elias
    Ravandi, Farhad
    Borthakur, Gautam
    Cortes, Jorge E.
    Kadia, Tapan
    O'Brien, Susan
    Thomas, Deborah A.
    Faderl, Stefan
    Bass, Joyce
    Wierda, William G.
    Daver, Naval
    DiNardo, Courtney D.
    Pierce, Sherry
    Brandt, Mark
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2013, 122 (21)
  • [36] A Phase II Expansion Study of Vorinostat in Combination With Idarubicin and Cytarabine for Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations
    Takahashi, Koichi
    Jabbour, Elias
    Ravandi, Farhad
    Borthakur, Gautam
    Cortes, Jorge
    Kadia, Tapan
    O'Brien, Susan
    Thomas, Deborah
    Faderl, Stefan
    Bass, Joyce
    Wierda, William
    Daver, Naval
    Dinardo, Courtney
    Pierce, Sherry
    Brandt, Mark
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S123 - S123
  • [37] Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia
    Apostolidou, E
    Cortes, J
    Tsimberidou, A
    Estey, E
    Kantarjian, H
    Giles, FJ
    LEUKEMIA RESEARCH, 2003, 27 (10) : 887 - 891
  • [38] A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)
    Murthy, Guru Subramanian Guru
    Kaufmann, Scott H.
    Szabo, Aniko
    Harrington, Alexandra M.
    Michaelis, Laura C.
    Abedin, Sameem
    Carlson, Karen
    Runaas, Lyndsey
    Longo, Walter L.
    Hinman, Alexander
    Maldonado-Schmidt, Sonia
    Thomas, Althea
    Baim, Arielle
    Litzow, Mark R.
    Atallah, Ehab L.
    BLOOD, 2021, 138
  • [39] High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
    Cortes, J
    Estey, E
    O'Brien, S
    Giles, F
    Shen, Y
    Koller, C
    Beran, M
    Thomas, D
    Keating, M
    Kantarjian, H
    CANCER, 2001, 92 (01) : 7 - 14
  • [40] Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
    Ikezoe, Takayuki
    Ando, Kiyoshi
    Onozawa, Masahiro
    Yamane, Takahisa
    Hosono, Naoko
    Morita, Yasuyoshi
    Kiguchi, Toru
    Iwasaki, Hiromi
    Miyamoto, Toshihiro
    Matsubara, Keisuke
    Sugimoto, Saori
    Miyazaki, Yasushi
    Kizaki, Masahiro
    Akashi, Koichi
    CANCER SCIENCE, 2022, 113 (12) : 4258 - 4266
12345